Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors

The vagus nerve is a mixed nerve, comprising 80% afferent fibers and 20% efferent fibers. It allows a bidirectional communication between the central nervous system and the digestive tract. It has a dual anti-inflammatory properties via activation of the hypothalamic pituitary adrenal axis, by its afferents, but also through a vago-vagal inflammatory reflex involving an afferent (vagal) and an efferent (vagal) arm, called the cholinergic anti-inflammatory pathway. Indeed, the release of acetylcholine at the end of its efferent fibers is able to inhibit the release of tumor necrosis factor (TNF) alpha by macrophages via an interneuron of the enteric nervous system synapsing between the efferent vagal endings and the macrophages and releasing acetylcholine. The vagus nerve also synapses with the splenic sympathetic nerve to inhibit the release of TNF-alpha by splenic macrophages. It can also activate the spinal sympathetic system after central integration of its afferents. This anti-TNF-alpha effect of the vagus nerve can be used in the treatment of chronic inflammatory bowel diseases, represented by Crohn’s disease and ulcerative colitis where this cytokine plays a key role. Bioelectronic medicine, via vagus nerve stimulation, may have an interest in this non-drug therapeutic approach as an alternative to conventional anti-TNF-alpha drugs, which are not devoid of side effects feared by patients.

Download Full-text

Mo1687 Oral Delivery of a New Class of Non-Antibody Protein Scaffold Nanofitins Targeting TNF-Alpha Shows a Strong Preventive and Curative Anti-Inflammatory Effect in Models of Inflammatory Bowel Diseases

Gastroenterology ◽

10.1016/s0016-5085(15)32317-9 ◽

2015 ◽

Vol 148 (4) ◽

pp. S-685

Author(s):

Christel Rousseaux ◽

Mathieu Cinier ◽

Magali Zeisser Labouebe ◽

Joao V. Rodrigues ◽

Antonio E. Cunha ◽

...

Keyword(s):

Inflammatory Bowel Diseases ◽

Oral Delivery ◽

Tnf Alpha ◽

Protein Scaffold ◽

New Class ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Anti Inflammatory ◽

Inflammatory Effect

Download Full-text

Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases

Medicine ◽

10.1097/md.0000000000019359 ◽

2020 ◽

Vol 99 (10) ◽

pp. e19359

Author(s):

Ana B. Grinman ◽

Maria das Graças C. de Souza ◽

Eliete Bouskela ◽

Ana Teresa P. Carvalho ◽

Heitor S. P. de Souza

Keyword(s):

Inflammatory Bowel Diseases ◽

Tnf Alpha ◽

Laboratory Markers ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Trough Levels

Download Full-text

Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population

Gastroenterology Research and Practice ◽

10.1155/2009/591704 ◽

2009 ◽

Vol 2009 ◽

pp. 1-9 ◽

Cited By ~ 11

Author(s):

Lynnette R. Ferguson ◽

Dug Yeo Han ◽

Claudia Huebner ◽

Ivonne Petermann ◽

Murray L. Barclay ◽

...

Keyword(s):

New Zealand ◽

Inflammatory Bowel Diseases ◽

Tumor Necrosis Factor Receptor ◽

Caucasian Population ◽

Tnf Alpha ◽

Indeterminate Colitis ◽

Nucleotide Polymorphisms ◽

Marker Haplotype ◽

Bowel Diseases ◽

Inflammatory Bowel

Inflammatory bowel diseases (IBDs) comprising Crohn disease (CD) and ulcerative colitis (UC) are chronic inflammatory conditions with polygenic susceptibility. Interactions between TNF-alpha and TNF-alpha receptor play a fundamental role in inflammatory response. This study investigates the role that selected single nucleotide polymorphisms (SNPs) and haplotypes in the TNF-alpha receptor (TNSFRSF1B) gene play in the risk of IBD in a New Zealand Caucasian population. DNA samples from 388 CD, 405 UC, 27 indeterminate colitis patients, and 293 randomly selected controls, from Canterbury, New Zealand were screened for 3 common SNPs in TNSFRSF1B: rs1061622 (c.676T>C), rs1061624 (c.∗1663A>G), and rs3397 (c.∗1690T>C), using TaqMan technologies. Carrying the rs1061624 variant decreased the risk of UC in the left colon (OR 0.73, 95% CI=0.54–1.00) and of being a smoker at diagnosis (OR 0.62; 95% CI=0.40–0.96). Carrying the rs3397 variant decreased the risk of penetrating CD (OR 0.62, 95% CI=0.40–0.95). Three marker haplotype analyses revealed highly significant differences between CD patients and control subjects (χ2=29.9,df=7,P=.0001) and UC cases and controls (χ2=46.3,df=7,P<.0001). We conclude that carrying a 3-marker haplotype in the TNSFRSF1B gene may increase (e.g., haplotype of GGC was 2.9-fold more in the CD or UCpatients) or decrease (e.g., TGT was 0.47-fold less in UC patients) the risk of IBD in a New Zealand Caucasian population.

Download Full-text